Proximal Ventures has raised $27.5 million for its first venture capital fund, targeting early-stage startups using artificial intelligence to improve pharmaceutical research, drug development, and related services. Founded by former SignalFire investor Sahir Raoof, the firm plans to invest in companies developing AI tools that help life sciences businesses reduce costs and improve operational efficiency.
The fundraising comes during a challenging period for first-time venture capital managers, as established investment firms continue attracting much of the available capital. Proximal Ventures has already invested in seven startups and plans to provide initial funding ranging from $500,000 to $1.5 million.
Proximal Ventures Targets AI in Pharmaceutical Services
The firm is focusing on the infrastructure and services supporting drug development rather than companies developing new medicines directly. Pharmaceutical businesses frequently outsource activities such as molecular synthesis, manufacturing preparation, clinical trial analysis, and research data management to specialized providers.
Raoof believes artificial intelligence can automate portions of these processes, allowing service providers to complete complex tasks faster and at lower costs. He sees opportunities for startups to develop AI-based alternatives to services that pharmaceutical companies already purchase.
Historically, pharmaceutical companies have been considered stronger customers for specialized services than standalone software products. Raoof argues that AI could change this relationship by combining software automation with established service delivery models.
He pointed to the growing adoption of AI in legal and financial services as examples of how technology can reshape industries dependent on specialized professional work.
Fund Backs Seven Early-Stage Startups
Proximal will primarily invest in pre-seed and seed-stage companies, with individual investments typically ranging from $500,000 to $1.5 million. Its portfolio already includes seven businesses developing technologies for different parts of the life sciences industry.
Among its investments is ChronicleBio, a startup co-founded by former OpenAI executive Fidji Simo. The company uses AI to analyze biological and medical information to better understand chronic diseases and identify potential treatments.
Raoof said startups selling into the pharmaceutical industry often struggle to establish their first commercial relationships. Proximal intends to support portfolio companies by helping them connect with potential customers and develop sustainable business models.
Healthcare Experience Helps Raoof Attract Investors
Before founding Proximal, Raoof spent two years as a principal at venture capital firm SignalFire. He previously led business development at clinical trial recruitment company Iterative Health and managed partnerships at Flatiron Health, an oncology data company acquired by Roche for $1.9 billion in 2018.
The fund’s investors include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and Dimension Capital co-founders Nan Li and Zavain Dar. Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the U.S. Food and Drug Administration, is also an investor.
Abernethy previously worked with Raoof at Flatiron Health, where she served as chief medical officer. She cited his understanding of healthcare industry challenges and ability to develop commercial relationships as reasons for supporting the fund.
Featured image credits: Magnific.com
For more stories like it, click the +Follow button at the top of this page to follow us.